Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

Condition:   Lyme Borreliosis Interventions:   Biological: VLA15;   Biological: Placebo Sponsor:   Valneva Austria GmbH Not yet recruiting

Source: ClinicalTrials.gov - December 7, 2018 Category: Research Source Type: clinical trials